<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002388</url>
  </required_header>
  <id_info>
    <org_study_id>238G</org_study_id>
    <secondary_id>CNAA1004</secondary_id>
    <nct_id>NCT00002388</nct_id>
  </id_info>
  <brief_title>A Study of 1592U89 in HIV-Infected Patients</brief_title>
  <official_title>A Study to Evaluate the Single-Dose and Steady-State Pharmacokinetics/Dynamics of 1592U89 and Its Active Moiety, 1144U88 5'-Triphosphate (1144U88-TP) Following Six Different Dosing Regimens of 1592U89 in HIV-1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe to give 1592U89 to HIV-infected patients.&#xD;
      This study also examines the effect 1592U89 has on plasma viral load (the level of HIV in the&#xD;
      blood).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cohorts of 8 patients are entered sequentially into 1 of 6 1592U89 dosing regimens. All&#xD;
      patients receive 12 weeks of monotherapy during the initial 12-week treatment phase.&#xD;
&#xD;
      On completion of the treatment phase, patients are offered continuation therapy with 1592U89&#xD;
      for a minimum of 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>48</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        Prophylaxis for opportunistic infections.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV-1 infection.&#xD;
&#xD;
          -  CD4 cell count 100 - 500 cells/mm3 within 3 to 5 weeks prior to study drug&#xD;
             administration.&#xD;
&#xD;
          -  No active diagnosis of AIDS (other than non-visceral Kaposi's sarcoma) according to&#xD;
             the 1993 CDC AIDS surveillance definition.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions and symptoms are excluded:&#xD;
&#xD;
          -  Malabsorption syndrome or other gastrointestinal dysfunction that may interfere with&#xD;
             drug absorption.&#xD;
&#xD;
          -  Chronic disease such as diabetes, congestive heart failure, cardiomyopathy, or other&#xD;
             cardiac dysfunction that in the opinion of the investigator, would compromise the&#xD;
             safety of the patient.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Immunomodulating agents.&#xD;
&#xD;
          -  Chemotherapeutic agents.&#xD;
&#xD;
          -  Antiretroviral therapy. NOTE:&#xD;
&#xD;
          -  Patients who elect to continue study treatment into the extended phase may, after&#xD;
             consultation with their primary physician, combine 1592U89 at a recommended dose of&#xD;
             300 mg bid with other licensed antiretroviral drugs.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Radiation therapy.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of clinically relevant hepatitis or pancreatitis within 6 months prior to&#xD;
             study drug administration.&#xD;
&#xD;
          -  History of hypersensitivity, anaphylactic, or idiosyncratic reaction to nucleoside&#xD;
             analogs.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Treatment with immunomodulating or cytotoxic chemotherapeutic agents within six weeks&#xD;
             prior to study drug administration.&#xD;
&#xD;
          -  Antiretroviral therapy within 2 weeks prior to administration of study drugs.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Radiation therapy within six weeks prior to study drug administration. Current alcohol or&#xD;
        illicit controlled substance use that in the opinion of the investigator, may interfere&#xD;
        with the patient's ability to complete the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Evanston Hosp / Clinical Pharmacology Unit</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fenway Community Health Ctr / Research Dept</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Med College / Albany Med Ctr Hosp</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 1998</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abacavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

